Men's big-and-tall retailer DXL is expecting, perhaps ironically, to benefit from the popularity of GLP-1 drugs such as ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

The United States has led the world in pharmaceutical innovation for decades by developing drugs that combat cancer, heart ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

Jim Cramer recently talked about the market selloff and how years of profits are lost within days when panic hits the market: ...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.